On 7 April 2022, Glenmark Pharmaceuticals repurchased an aggregate
principal amount of US$75,000,000 of the US$200,000,000 2.00 per cent Resettable Onward Starting Equity-linked Securities Due 2022 (ISIN: XS1426780125; Common Code: 142678012) (Bonds) (Repurchase).
The Repurchase was carried out by way of on-market purchases via The Hongkong and Shanghai Banking Corporation. The Bonds are listed on the Singapore Exchange Securities Trading.
The settlement and cancellation for the repurchased Bonds had completed on 7 April 2022. Following cancellation, the aggregate outstanding principal amount of the Bonds will be US$750,000.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
